Ames negative; negative for clastogenicity in human fibroblasts; increased micronuclei in human lymphocytes in vitro
“Trilaciclib was negative for mutagenic potential in the Ames assays and negative for clastogenic potential in primary human fibroblasts. Trilaciclib increased micronucleus formation in human peripheral blood lymphocytes in vitro, suggesting clastogenic activity.”
✓ VerifiedFDA pharmacology/toxicology review, p. 65Source ↗
Carcinogenicity
Not conducted
“Carcinogenic potential of trilaciclib has not been assessed in animals.”
✓ VerifiedFDA pharmacology/toxicology review, p. 70Source ↗
Reproductive & developmental
Not conducted (no fertility, developmental or reproductive toxicity studies)
“No fertility, developmental, or reproductive toxicity studies were conducted in animals.”
✓ VerifiedFDA pharmacology/toxicology review, p. 71Source ↗
Safety pharmacology
Low-potency hERG inhibition (IC50 ≈20 μM) and increased heart rate in dogs; no QT prolongation in animal studies
“There were signals for potential cardiovascular effects of trilaciclib based on a low potency in vitro signal for hERG inhibition (IC50 ≈ 20 μM) and increased heart rate in dogs. In vitro hERG inhibition is a biological marker of QT prolongation but no QT prolongation was observed in animal studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 9Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative